Green Cross Voluntarily Withdraws Conditional Approval Application for COVID-19 Plasma Treatment Zicoviddic Injection

[Asia Economy Reporter Oh Ju-yeon] Green Cross announced on the 4th that it will voluntarily withdraw its conditional marketing authorization application for the COVID-19 plasma treatment Zicoviddic Injection submitted to the Ministry of Food and Drug Safety.

The company stated, "Based on the initial Phase 2 clinical trial results of Zicoviddic Injection conducted at 13 domestic clinical trial institutions, we applied for domestic marketing authorization and have been under review by the Ministry of Food and Drug Safety. The Ministry recommended submitting additional clinical results that can confirm the treatment efficacy after internal review of the submitted clinical trial results and meetings with the 'COVID-19 Therapeutics Safety and Efficacy Verification Advisory Committee.' We accepted the review opinion and voluntarily withdrew the applied marketing authorization," the company explained.